Dr. Maureen P. Reilly Tells Audience "the PSA 4000 empowers me to be as

precisely in control as professionally possible,

and that's superior medicine."

NO. BILLERICA, Mass., June 27 /PRNewswire/ --

Physiometrix Inc. (Nasdaq: PHYX), developer of the patented

Patient State Analyzer (PSA 4000), a novel anesthesia-monitoring system that enables clinicians to assess and manage a patient's level of consciousness during surgery, announced that Maureen P. Reilly, Ph.D., CRNA, a clinical researcher and anesthetist at San Antonio, Texas-based South Texas Veterans Health Care System, told a gathering last week in New York City that she believes "the PSA 4000 gives me a whole new level of critical information about my patient, in an easy-to-use and real-time format, that empowers me to be as precise as possible in administering care." (Dr. Reilly has no equity interest in Physiometrix.)

Last week's meeting was the third in a series of three educational meetings this month in which leading anesthesia providers presented their personal clinical experiences using the PSA 4000 and also participated in a question-and-answer session with the audience and Company management. The New York City meeting was videotaped, and Dr. Reilly's commentary will be made available on the Physiometrix Web site (www.physiometrix.com).

"I use the PSA 4000 all of the time," said Dr. Reilly, "because it gives me reliable information I need to be in total control for my patient's benefit. For that reason, I believe PSA 4000 will in time become the standard of care in monitoring consciousness. In particular, elderly patients and high-risk patients presenting with multiple co-morbidities should be monitored."

Dr. Maureen Reilly has been a staff anesthetist at South West Texas Veterans Health Care System since 1996. In addition, Dr. Reilly is an adjunct associate professor at the University of Texas Health Science Center, and a member of the Editorial Review Board for Anesthesia Today. Her clinical research has been published in journals such as Anesthesia Today, Geriatric Nursing, and Seminars in Perioperative Nursing, among others.

PSA 4000 is a device that enables anesthesiologists to monitor and manage a patient's level of consciousness during surgery, with the potential to enhance patient care, improve recovery times and save lives in hospitals across the U.S. and around the world. Physiometrix Inc. designs, manufactures and markets noninvasive medical products -- based on novel gel materials, sophisticated signal-processing electronics technologies, and proprietary software -- for use in anesthesia-monitoring applications during surgical procedures.

Statements in this press release regarding Physiometrix's growth and future business results of the Company are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain and actual performance and results may differ materially due to many important factors. Such factors that could cause actual results to differ materially from any forward-looking statements made by the Company include, among others, dependence on existing and future products, uncertainty of market acceptance, intense competition, partnership agreements, and government regulations, especially regulatory approvals. Other relevant risks are described in the Company's Form 10-K filed March 29, 2001, with the SEC.

CONTACTS:

Daniel W. Muehl, CFO

Physiometrix Inc.

978-670-2422

Susan E. Burke

Ronald Trahan Associates, Inc.

508-647-9782, ext. 20

MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X75879134